About DNA damage-binding protein 2
DNA damage-binding protein 2 (DDB2) is a protein
from Homo sapiens identified by UniProt accession
Q92466, 427 residues long.
MolForge cross-references it against 0 known binders and
244 disease associations.
Target properties
| Protein name | DNA damage-binding protein 2 |
| UniProt accession | Q92466 |
| Gene | DDB2 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (244)
Diseases linked to this target (Open Targets).
- xeroderma pigmentosum group E · score 0.79
- Xeroderma pigmentosum complementation group E · score 0.56
- xeroderma pigmentosum · score 0.42
- hemangioblastoma · score 0.37
- prostate carcinoma · score 0.37
- Ovarian Endometrioid Adenocarcinoma with Squamous Differentiation · score 0.37
- skin basal cell carcinoma · score 0.37
- head and neck squamous cell carcinoma · score 0.34
- acute myeloid leukemia · score 0.33
- squamous cell lung carcinoma · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92466-F1 | alphafold | PREDICTED | 83.59 | — |
Amino-acid sequence (427 residues)
MAPKKRPETQ KTSEIVLRPR NKRSRSPLEL EPEAKKLCAK GSGPSRRCDS DCLWVGLAGP QILPPCRSIV RTLHQHKLGR ASWPSVQQGL QQSFLHTLDS YRILQKAAPF DRRATSLAWH PTHPSTVAVG SKGGDIMLWN FGIKDKPTFI KGIGAGGSIT GLKFNPLNTN QFYASSMEGT TRLQDFKGNI LRVFASSDTI NIWFCSLDVS ASSRMVVTGD NVGNVILLNM DGKELWNLRM HKKKVTHVAL NPCCDWFLAT ASVDQTVKIW DLRQVRGKAS FLYSLPHRHP VNAACFSPDG ARLLTTDQKS EIRVYSASQW DCPLGLIPHP HRHFQHLTPI KAAWHPRYNL IVVGRYPDPN FKSCTPYELR TIDVFDGNSG KMMCQLYDPE SSGISSLNEF NPMGDTLASA MGYHILIWSQ EEARTRK
Explore DNA damage-binding protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets